Skip to main content
Top

15-12-2022 | JAK inhibitors | News

Regulatory update

EMA restricts JAK inhibitor use in high-risk patient groups

Author: Claire Barnard

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has announced measures to reduce the risk for serious adverse events associated with Janus kinase (JAK) inhibitors in patients with immunoinflammatory diseases.

For certain high-risk groups, the agency says that these medicines should only be used “if no suitable treatment alternatives are available.” These groups include people aged 65 years and older and those with risk factors for cardiovascular disease, cancer, and venous thromboembolism. If it is necessary to use JAK inhibitors in these patients, the agency recommends that doses should be reduced if possible.

Click through to watch Victoria Ruffing’s guidance on how to talk to patients about the risks associated with JAK inhibitors 

These recommendations are based on a data review, comprising findings from the ORAL Surveillance trial, preliminary results from an observational study of baricitinib, and expert advice from a multidisciplinary group.

The EMA’s advice follows an announcement from the US FDA, which stated that the labels for all currently approved JAK inhibitors must include boxed warnings with information on the risks, and that use of these agents is only permitted in patients with an inadequate response or intolerance to tumor necrosis factor inhibitors.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

share
SHARE
print
PRINT

Related content

11-08-2021 | JAK inhibitors | Feature | Article

JAK inhibitor safety: Distilling the evidence

Peter Nash discusses the latest evidence on the association between JAK inhibitors and the risk for VTE, MACE, and malignancy